Allergan Drug Analysis & Outlook (2016-2026) - Generic Pressures - Tucson News Now

Allergan Drug Analysis & Outlook (2016-2026) - Generic Pressures Loom in 2018

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact

SOURCE Research and Markets

DUBLIN, March 6, 2018 /PRNewswire/ --

The "Drug analysis: Allergan" drug pipelines has been added to's offering.

Research and Markets Logo

Allergan's prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016-2026 is explored.


  • Overview - Allergan will finish 2017 positively with pharmaceutical revenues of $15.7bn, up 8% from FY2016, although generic pressures loom in 2018.
  • Mid-term outlook - Botox and the successful launch of Vraylar are driving Allergan's pharmaceutical revenue growth, together adding over $2.4bn in sales out to 2021.
  • Long-term outlook - Topline revenue will climb to reach around $20bn by 2025, driven by the growth of Botox, as well as the CNS and gastroenterology portfolios.
  • Pipeline - Allergan has focused its resources on six star R&D programs that, if successful, will drive long-term growth.
  • Events - A Refuse to File letter has been issued for Vraylar for the treatment of PNS, as Esmya is filed for approval for use in uterine fibroids.


  • Allergan has divested its generics and Anda businesses to its shift focus to branded pharmaceuticals.
  • Allergan's CNS portfolio will expand due to the growth of new drugs to treat neurological disorders.
  • Allergan's genitourinary portfolio will grow by $181m out to 2026, carried by sales of the oral contraception franchise Lo Loestrin Fe and the launch of pipeline candidate Esmya.
  • During 2016-26, the gastroenterology portfolio will grow at a 10.2% CAGR, driven by best-in-class Linzess and Viberzi in IBS.

Model Updates

  • Kybella sales downgraded.
  • Vraylar supplementary approval treating PNS delayed.
  • Restasis generic competition brought forward to Q4 2018.
  • Revised Rhofade sales.

Key Topics Covered:

1. Executive Summary

2. Q2 2017 Review

  • Increased R&D investment
  • Pipeline update
  • Recent launches
  • Growth outlook
  • Bold intellectual property protection

3. Q3 2017 Review

  • Allergan reports solid quarter as generic pressures loom in 2018

4. Company Context

  • Acquisition trail
  • Growth Pharma
  • Pfizer terminated plans for Allergan combination
  • Allergan's transformation to branded growth pharma
  • 2017 outlook: acquisitions and R&D spending
  • Allergan's SWOT analysis
  • Allergan's key events and catalysts

5. Facts and Figures

  • Allergan's prescription pharma sales outlook
  • Allergan's therapy area dynamics
  • Allergan's regional pharma sales outlook
  • Allergan's top 10 products over 2016-26
  • Allergan's growth drivers and resistors
  • Allergan's launch/core/expiry analysis
  • Allergan's financial outlook
  • Allergan's M&A history

6. Therapy Area Analysis

  • Botox will provide sustained growth across both therapeutic and cosmetic indications
  • Additional therapeutic indications are not included in the forecast
  • Central nervous system
  • Genitourinary
  • Gastroenterology

For more information about this drug pipelines report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


Cision View original content:

©2017 PR Newswire. All Rights Reserved.

Powered by Frankly